93 related articles for article (PubMed ID: 16551846)
1. Is BRAF the Achilles' Heel of thyroid cancer?
Chiloeches A; Marais R
Clin Cancer Res; 2006 Mar; 12(6):1661-4. PubMed ID: 16551846
[No Abstract] [Full Text] [Related]
2. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
3. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.
King AJ; Patrick DR; Batorsky RS; Ho ML; Do HT; Zhang SY; Kumar R; Rusnak DW; Takle AK; Wilson DM; Hugger E; Wang L; Karreth F; Lougheed JC; Lee J; Chau D; Stout TJ; May EW; Rominger CM; Schaber MD; Luo L; Lakdawala AS; Adams JL; Contractor RG; Smalley KS; Herlyn M; Morrissey MM; Tuveson DA; Huang PS
Cancer Res; 2006 Dec; 66(23):11100-5. PubMed ID: 17145850
[TBL] [Abstract][Full Text] [Related]
4. BRAF is a therapeutic target in aggressive thyroid carcinoma.
Salvatore G; De Falco V; Salerno P; Nappi TC; Pepe S; Troncone G; Carlomagno F; Melillo RM; Wilhelm SM; Santoro M
Clin Cancer Res; 2006 Mar; 12(5):1623-9. PubMed ID: 16533790
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.
Liu D; Liu Z; Jiang D; Dackiw AP; Xing M
J Clin Endocrinol Metab; 2007 Dec; 92(12):4686-95. PubMed ID: 17911174
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth.
Ezzat S; Huang P; Dackiw A; Asa SL
Clin Cancer Res; 2005 Feb; 11(3):1336-41. PubMed ID: 15709206
[TBL] [Abstract][Full Text] [Related]
7. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of RET tyrosine kinase by SU5416.
Mologni L; Sala E; Cazzaniga S; Rostagno R; Kuoni T; Puttini M; Bain J; Cleris L; Redaelli S; Riva B; Formelli F; Scapozza L; Gambacorti-Passerini C
J Mol Endocrinol; 2006 Oct; 37(2):199-212. PubMed ID: 17032739
[TBL] [Abstract][Full Text] [Related]
9. New approaches to thyroid cancer.
Cohen EE
Clin Adv Hematol Oncol; 2012 Apr; 10(4):255-6. PubMed ID: 22706487
[No Abstract] [Full Text] [Related]
10. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside.
Choi HJ; Kim TY; Chung N; Yim JH; Kim WG; Kim JA; Kim WB; Shong YK
J Endocrinol; 2011 Oct; 211(1):79-85. PubMed ID: 21795305
[TBL] [Abstract][Full Text] [Related]
11. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y
J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
[TBL] [Abstract][Full Text] [Related]
12. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
13. [Frequency of RET/PTC rearrangement and somatic BRAF mutation in papillary thyroid cancer].
Rumiantsev PO; Zaletaev DV; Vasil'ev EV; Saenko VA; Il'in AA; Rumiantseva UV; Abrosimov AIu; Medvedev VS
Vopr Onkol; 2006; 52(2):145-9. PubMed ID: 17195637
[TBL] [Abstract][Full Text] [Related]
14. Drug discovery: inhibitors that activate.
Cichowski K; Jänne PA
Nature; 2010 Mar; 464(7287):358-9. PubMed ID: 20237552
[No Abstract] [Full Text] [Related]
15. RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase.
De Falco V; Castellone MD; De Vita G; Cirafici AM; Hershman JM; Guerrero C; Fusco A; Melillo RM; Santoro M
Cancer Res; 2007 Jan; 67(1):381-90. PubMed ID: 17210721
[TBL] [Abstract][Full Text] [Related]
16. Targeting BRAF in thyroid cancer.
Espinosa AV; Porchia L; Ringel MD
Br J Cancer; 2007 Jan; 96(1):16-20. PubMed ID: 17179987
[TBL] [Abstract][Full Text] [Related]
17. Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer.
Santoro M; Carlomagno F
Nat Clin Pract Endocrinol Metab; 2006 Jan; 2(1):42-52. PubMed ID: 16932252
[TBL] [Abstract][Full Text] [Related]
18. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
19. RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components.
Mochizuki K; Kondo T; Nakazawa T; Iwashina M; Kawasaki T; Nakamura N; Yamane T; Murata S; Ito K; Kameyama K; Kobayashi M; Katoh R
Histopathology; 2010 Sep; 57(3):444-50. PubMed ID: 20840674
[TBL] [Abstract][Full Text] [Related]
20. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.
Petrangolini G; Cuccuru G; Lanzi C; Tortoreto M; Belluco S; Pratesi G; Cassinelli G; Zunino F
Biochem Pharmacol; 2006 Aug; 72(4):405-14. PubMed ID: 16756963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
